

Innoforce Completes Second Tranche of Series A Financing

HANGZHOU

December 6, 2021

Innoforce (“INF”), a biopharmaceutical manufacturing & development company, announced today the completion of a **1 billion CNY (\$156.6M)** Series A financing, with the closing of an additional **375M CNY (\$58.7M)** following the first tranche of **625M CNY (\$96M)** completed in March 2021.

The Series A financing round was co-led by Yanchuang Capital and South China Venture Capital (SCVC) with additional investment from existing investor Quan Capital Management. In the most recent tranche, Yanchuang Capital increased its investment and additional investors joined, including Advantech Capital, Triwise Capital, CICC Capital, Highrun Capital, Euland Venture, S&G CAPITAL and others.

Proceeds will advance INF’s GMP biomanufacturing capabilities, including establishing its cell & gene therapies capacity and additional investment in the development of an RNA manufacturing platform.

The financing will also support the continued advancement of biopharmaceutical R&D facilities at INF’s campus, which will be a platform to create tailored partnerships with entrepreneurial scientists & companies for drug development, operations management, and support services.

“We are extremely proud of the near completion of the first phase of construction of the Innoforce campus in Hangzhou and our progress towards planned, staged GMP operations in the coming year. Our fundraising activities have enabled establishing our joint venture with biologics manufacturing, opening our process development laboratories, and building our team,” said **Dr. Yuling Li, CEO of Innoforce**. “We are thankful for the tremendous support from our investors and appreciate the confidence they have placed in our team.”

“Cell, gene & RNA therapies represent among the greatest opportunities for breakthrough innovation in the biomedical field. We are thrilled to support Innoforce in building a unique platform that will help partners realize the potential of these & other technologies to transform the way we treat diseases,” said **Ms. Liu Zeng, CEO of Yanchuang Capital.**

Mr. Benjamin Yumin Qiu, Head of Healthcare investment at Advantech Capital, further commented, “We are pleased to support the Innoforce team as they establish their manufacturing & development capabilities that will make them a strong partner enabling innovation of advanced cell, gene, RNA & biologic therapies.”

About Innoforce

Innoforce is a partnership-focused biopharmaceutical company established to enable and accelerate the innovation of breakthrough medicines. The company has world-class biopharmaceutical manufacturing and development capabilities to serve global markets at our campus in Hangzhou, China, and offices in Rockville, Maryland. Innoforce offers end-to-end contract development and manufacturing service (CDMO), including GMP manufacturing of plasmid DNA, RNA, viral vector, and cell products by the middle of 2022. In addition, through a joint venture with a leading international supplier of life sciences products & services, the company provides CDMO services for antibody and protein drugs. Innoforce’s enabling capabilities for incubating and developing cell, gene, and advanced biological therapies can support partners and portfolio companies to rapidly and efficiently bring cutting-edge treatments that impact patients' lives worldwide. More information is available at www.innoforcepharma.com.

健新原力完成 A 轮两期融资

杭州

2021 年 12 月 6 日

浙江健新原力制药有限公司(简称“健新原力”),一家专注于生物制药生产和开发的公司,今天宣布完成 **10 亿元人民币(约 1.566 亿美元)**的 **A 轮融资**,这是健新原力在 **2021 年 3 月完成 6.25 亿元人民币(约 9600 万美元)**的第一期 **A 轮融资**以后的又一期 **3.75 亿元人民币(约 5870 万美元)**的融资。

本次 **A 轮融资**由燕创资本和中南创投(**SCVC**)联合领投,原有股东泉创资本继续加持,并有尚城资本、勤智资本、中金资本旗下基金(**CICC**)、开投瀚润、优地资本、和源道投资等其他投资者跟投。

本轮融资资金将加速提升健新原力的 **GMP** 生物制药产能,包括建立其细胞和基因治疗产能以及 **RNA** 生产制造平台开发所需的额外投资。资金还将支持位于健新原力园区内的生物制药研发设施的持续建设。该园区将为创业科学家合作伙伴们提供量身定制的药物开发、运营管理等服务,以及对创业公司的广泛支持。

“我们对健新原力在杭州的园区第一阶段建设的即将竣工,以及我们在来年按计划、分阶段实施 **GMP** 生物制药产能的运营取得的进展感到非常自豪。我们的融资使我们能够与生物制品制药公司建立合资企业,扩展我们的工艺开发实验室和我们的团队,”**健新原力首席执行官李玉玲博士**说,“我们感谢投资者的大力支持,感谢他们对我们团队的信心。”

“细胞、基因和 **RNA** 疗法代表了生物医学领域突破性创新的最大机遇。我们很高兴能支持健新原力去建立一个独特的平台以帮助合作伙伴实现这些技术创新以及其他技术的潜力,期望最终改变我们治疗疾病方式,”**燕创资本首席执行官刘增女士**说。

尚城资本医疗投资主管裘育敏先生进一步表示,“我们很高兴能够支持健新原力团队建立他们的生产和开发能力,这将使他们成为赋能先进的细胞、基因、**RNA** 和生物疗法创新的强大合作伙伴。”

关于**健新原力**

健新原力是一家专注于创新和伙伴合作的生物制药公司,旨在促进和加速突破性药物的创新。公司拥有世界一流的生物制药生产和开发能力,我们将使用位于中国杭州的工厂和美国马里兰州 **Rockville** 的办事处服务全球市场。健新原力将在 **2022** 年年中提供端到端的生产外包服务(**CDMO**),其中包括质粒 **DNA**、**RNA**、病毒载体和细胞治疗产

品的 **GMP** 商业化生产。此外,健新原力还将通过与一家世界领先生命科学产品和服务供应商的合资企业为抗体和蛋白质药物提供 **CDMO** 服务。健新原力在孵化和开发细胞治疗、基因治疗等先进生物疗法方面的能力,能够支持合作伙伴和投资组合公司更高效地推出影响全球患者生活的尖端疗法。

更多信息请访问 www.innoforcepharma.com。